Biogen hands over $45M cash to license a tau project for Alzheimer's; Novartis launches a lottery for free dose of the world's priciest drug
→ Biogen isn’t done gambling on Alzheimer’s. The big biotech is paying Ionis $45 million upfront to license their antisense …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
